IP Library Granted Patent US 12,447,177
Granted Patent B2
US 12,447,177 · App. 17/292,597 · Granted Oct 21, 2025

Methods for managing adverse events in patients with inflammation

Inventors: Andrew Dunham (Tower Lakes, IL); Tatsuro Yoshida (West Newton, MA); Samuel O. Sowemimo-Coker (Dix Hills, NY)
Assignee: Hemanext Inc.
A61K35/14A61P7/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,177
App. No.
17/292,597
Granted
Oct 21, 2025
Kind
B2
Abstract

Methods for prevention and reversal of inflammation.

Claims (9)

1. A method of treating elevated c-reactive protein (CRP) in a patient in need thereof comprising administering stored oxygen reduced blood having an oxygen saturation of 20% or less during storage to a patient in need thereof having both elevated CRP and inflammation, wherein the elevated CRP level is between 5 and 10 milligrams per liter (mg/L) prior to the administering, and wherein the administering reduces the elevated CRP level in the patient in need thereof by at least 20% relative to a CRP level of a patient having both elevated CRP and inflammation and having been administered conventionally stored, non-oxygen reduced blood.

2. The method of claim 1 , wherein the stored oxygen reduced blood is stored oxygen and carbon dioxide reduced blood.

3. The method of claim 1 , wherein the inflammation is due to trauma, infection, cancer, coagulopathy, or autoimmunity.

4. The method of claim 1 , wherein the patient in need thereof further has a fever or is at risk of developing a fever.

5. The method of claim 4 , wherein the patient in need thereof has increased levels of one or more inflammatory mediators selected from the group consisting of interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), and granulocyte-colony stimulating factor (G-CSF), compared to a patient having elevated CRP and inflammation but without a fever.

6. The method of claim 4 , wherein the patient in need thereof has decreased levels of one or more inflammatory mediators selected from the group consisting of chemokine (C-C motif) ligand 5 (CCL5) and C-X-C motif chemokine ligand 10 (CXCL10), compared to a patient having elevated CRP and inflammation but without a fever.

7. The method of claim 1 , wherein the patient in need thereof has liver damage, lung damage, splenic damage, kidney damage, bone damage, or any combination thereof.

8. The method of claim 1 , wherein the treating comprises reducing red blood cell adhesion to thrombospondin in the patient in need thereof by at least 10% compared to red blood cell adhesion to thrombospondin in a patient having elevated CRP and inflammation and having been administered conventionally stored, non-oxygen reduced blood.

9. The method of claim 1 , wherein the elevated CRP level in the patient in need thereof is reduced to less than 3 milligrams per liter (mg/L) after the administering.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: DUNHAM, ANDREW; YOSHIDA, TATSURO; SOWEMIMO-COKER, SAMUEL O.
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 062452/0918 →
CHANGE OF NAME Recorded Jan 23, 2023
From: NEW HEALTH SCIENCES, INC.
To: HEMANEXT INC.
Reel/Frame 062461/0619 →
Continuity (2)
Provisional Application 62768667 · Nov 16, 2018
Related Publication 20210401883A1 · Dec 30, 2021
References Cited (70)
US 4769318A · Hamasaki et al. · 1988 [cited by applicant]
US 4880786A · Sasakawa et al. · 1989 [cited by applicant]
US 5476764A · Bitensky · 1995 [cited by applicant]
US 5624794A · Bitensky et al. · 1997 [cited by applicant]
US 5789151A · Bitensky et al. · 1998 [cited by applicant]
US 6162396A · Bitensky et al. · 2000 [cited by applicant]
US 6413713B1 · Serebrennikov · 2002 [cited by applicant]
US 6447987B1 · Hess et al. · 2002 [cited by applicant]
US 10603417B2 · Yoshida et al. · 2020 [cited by applicant]
US 11013771B2 · Yoshida · 2021 [cited by examiner]
US 11090331B2 · D'Alessandro · 2021 [cited by examiner]
US 11433164B2 · Yoshida et al. · 2022 [cited by applicant]
US 11576931B2 · Dunham · 2023 [cited by examiner]
US 20120129149A1 · Federspiel et al. · 2012 [cited by applicant]
US 20130004937A1 · Yoshida et al. · 2013 [cited by applicant]
US 20230248767A1 · Dunham et al. · 2023 [cited by applicant]
CN 103037869A · 2013 [cited by applicant]
CN 103732056A · 2014 [cited by applicant]
CN 107735095A · 2018 [cited by applicant]
WO WO2016187353A1 · 2016 [cited by applicant]
WO WO2017223377A1 · 2017 [cited by applicant]
WO WO2020102602 · 2020 [cited by applicant]
International Search Report dated Jan. 31, 2020 in Int'l Appln. PCT/US2019/061565. [cited by applicant]
Search Report dated Dec. 4, 2023 issued in Chinese Appln. 2019800791920. [cited by applicant]
Brown et al., “Length of red cell unit storage and risk for delirium after cardiac surgery,” [cited by applicant]
Chaplin et al., “The proper use of previously frozen red blood cells for transfusion,” [cited by applicant]
Ciccia et al., “Pediatric acute kidney inquy: prevalence, impact and management challenges,” [cited by applicant]
D'Alessandro et al., “An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies,” [cited by applicant]
D'Alessandro et al., “Citrate metabolism in red blood cells stored in additive solution-3,” [cited by applicant]
D'Alessandro et al., “Metabolomics of AS-5 RBC supernatants following routine storage,” [cited by applicant]
D'Alessandro et al., “Omics markers of the red cell storage lesion and metabolic linkage,” [cited by applicant]
D'Alessandro et al., “Red blood cell storage in additive solution-7 preserves energy and redox metabolism: a metabolomics approach,” [cited by applicant]
D'Alessandro et al., “Routine storage of red blood cell (RBC) units in additive solution-3: a comprehensive investigation of the RBC metabolome,” [cited by applicant]
Flegel et al., “Does prolonged storage of red blood cells cause harm?” [cited by applicant]
Fox et al., “Earlier Endpoints Are Required for Hemorrhagic Shock Trials among Severely Injured Patients,” [cited by applicant]
Gowda, et al., “Markers of renal function tests,” [cited by applicant]
Hashmi et al., “Predictors of mortality in geriatric trauma patients: A systematic review and meta-analysis,” [cited by applicant]
Hod et al., “Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron,” [cited by applicant]
Jy et al., “Microparticles in stored red blood cells as potential mediators of transfusion complications,” [cited by applicant]
Kim-Shapiro et al., “Storage lesion: role of red blood cell breakdown,” [cited by applicant]
Kleiner., et al., “Cytokine Levels in the Serum of Healthy Subjects,” [cited by applicant]
Kreutziger et al., “Admission blood glucose predicted haemorrhagic shock in multiple trauma patients,” [cited by applicant]
Laird et al., “Relationship of Early Hyperglycemia to Mortality in Trauma Patients,” [cited by applicant]
Liu et al., “Mechanism of faster NO scavenging by older stored red blood cells,” [cited by applicant]
Norton, et al., “Injuries,” [cited by applicant]
Platt, “Sickle cell anemia as an inflammatory disease,” [cited by applicant]
Prestia et al., “Transfusion of stored blood impairs host defenses against Gram-negative pathogens in mice,” [cited by applicant]
Redlin et al., “Red Blood Cell Storage Duration Is Associated with Various Clinical Outcomes in Pediatric Cardiac Surgery,” [cited by applicant]
Régnier et al., “Prognostic Significance of Blood Lactate and Lactate Clearance in Trauma Patients,” [cited by applicant]
Reisz et al., “Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells e-blood,” [cited by applicant]
Reynolds et al., “The transfusion problem: role of aberrant S-nitrosylation,” [cited by applicant]
Roback et al., “Insufficient nitric oxide bioavailability: a hypothesis to explain adverse effects of red blood cell transfusion,” [cited by applicant]
Roback et al., “Metabolomics of ADSOL (AS-1) Red Blood Cell Storage,” [cited by applicant]
Rogers et al., “Storage Duration of Red Blood Cell Transfusion and [cited by applicant]
Spinella et al., “Does the storage duration of blood products affect outcomes in critically ill patients?” [cited by applicant]
Spinella et al., “Properties of stored RBCs: Understanding immune and vascular reactivity,” [cited by applicant]
Treeprasertsuk et al., “Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions,” [cited by applicant]
Valenri et al., “The survival, function, and hemolysis of human RBCs stored at 4° C. in additive solution (AS-1, AS-3, or AS-5) for 42 days and then biochemically modified, frozen, thawed, washed, and stored at 4° C. in… [cited by applicant]
Wang et al., “Transfusion of older stored blood worsens outcomes in canines depending on the presence and severity of pneumonia,” [cited by applicant]
Weinberg et al., “Red blood cell age and potentiation of transfusion-related pathology in trauma patients,” [cited by applicant]
Wither et al., “Hemoglobin oxidation at functional amino acid residues during routine storage of red blood cells,” [cited by applicant]
Yoshida et al., “Extended storage of red blood cells under anaerobic conditions,” [cited by applicant]
Yoshida et al., “The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells,” [cited by applicant]
Yoshida et al. “Reduction of microparticle generation during anaerobic storage of red blood cells,” [cited by applicant]
Zhang et al., “Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis,” [cited by applicant]
Zhu et al., “Impaired adenosine-5′ triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism of hypoxemia after transfusion,” [cited by applicant]
Zimring, “Established and theoretical factors to consider in assessing the red cell storage lesion,” [cited by applicant]
He at al., “24. Effect of Active Oxygen on the Rheological Properties of Red Aluminum, Its Mechanism and Its Electrochemical Significance,” [cited by applicant]
Hu et al., “18. Pleural Effusion and ascites,” [cited by applicant]
[cited by applicant]